Jade Biosciences (JBIO) Prepaid Assets (2020 - 2026)
Jade Biosciences' (JBIO) quarterly Prepaid Assets came in at $7.2 million in Q1 2026, up 520.98% YoY from $1.2 million in Q1 2025, and down 42.95% on a QoQ basis from $12.7 million in Q4 2025.
Analysis
Jade Biosciences (JBIO) Prepaid Assets (2020 - 2026) Analysis & Trends
Jade Biosciences (JBIO) has 7 years of Prepaid Assets data on file, last reported at $7.2 million in Q1 2026.
- Quarterly Prepaid Assets rose 520.98% year-over-year to $7.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.2 million (up 520.98% YoY) and the FY2025 annual result came in at $12.7 million, up 4623.13% from the prior year.
- Prepaid Assets retreated to $7.2 million in Q1 2026, from $12.7 million in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $12.7 million in Q4 2025 to a low of $168000.0 in Q3 2023.
- A 5-year average of $2.2 million and a median of $1.1 million in 2023 frame the typical range for Prepaid Assets.
- Annual changes were most pronounced in 2023 — Prepaid Assets sank 89.02% — and 2025, when it surged 4623.13%.
- Tracing JBIO's Prepaid Assets over 5 years: stood at $2.3 million in 2022, then slumped by 89.02% to $250000.0 in 2023, then grew by 7.2% to $268000.0 in 2024, then surged by 4623.13% to $12.7 million in 2025, then slumped by 42.95% to $7.2 million in 2026.
- The last three Prepaid Assets figures came in at $7.2 million (Q1 2026), $12.7 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Jade Biosciences | 1.21 Bn | 1.21 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 10.05 Mn |
| Mar 31, 2026 | 7.22 Mn |
| Dec 31, 2025 | 12.66 Mn |
| Sep 30, 2025 | 2.46 Mn |
| Jun 30, 2025 | 2.04 Mn |
| Mar 31, 2025 | 1.16 Mn |
| Dec 31, 2024 | 268,000.00 |
| Sep 30, 2024 | 1.88 Mn |
| Jun 30, 2024 | 6.56 Mn |
| Mar 31, 2024 | 3.91 Mn |
| Dec 31, 2023 | 1.79 Mn |
| Sep 30, 2023 | 2.40 Mn |
| Jun 30, 2023 | 2.37 Mn |
| Mar 31, 2023 | 1.64 Mn |
| Dec 31, 2022 | 2.28 Mn |
| Sep 30, 2022 | 2.58 Mn |
| Jun 30, 2022 | 1.46 Mn |
| Mar 31, 2022 | 4.81 Mn |
| Dec 31, 2021 | 6.96 Mn |
| Sep 30, 2021 | 2.22 Mn |